Anti-Psychotic Drug Enters Phase II Trials

LY2140023, an anti-psychotic drug developed by Eli Lilly and Company, has entered phase II proof of concept trials today. The drug activates glutamate receptor mGlu2/3, and has been shown to display fewer side effects than already available anti-psychotic drugs while still improving the quality of life for schitzophrenics.

I found this article interesting because of its ties into our brain project. By modifying a single receptor protein, LY2140023 is able to change biochemical pathways to the extent that it manifests itself behaviorally. Even more interesting are the side effects of the medicine, and the glimpses into the segue between brain chemistry and organism function. The article can be found at: http://www.medpagetoday.com/Psychiatry/GeneralPsychiatry/tb/6611